Somatropin Market is Estimated to Witness High Growth Owing to Opportunity in Treatment of Pediatric Growth Disorders

Somatropin, also known as human growth hormone, is a peptide hormone that stimulates growth, cell reproduction, and cell regeneration in humans and other animals. It is most commonly used to treat growth failure and growth hormone deficiency in children and adults. Somatropin is administered through daily subcutaneous injections. It serves to stimulate cellular growth and division through insulin-like growth factor 1 in patients suffering from conditions like Turner syndrome, Prader-Willi syndrome, chronic renal failure, and idiopathic short stature.

The global Somatropin market is estimated to be valued at US$ 3.85 Bn in 2023 and is expected to exhibit a CAGR of 7.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics: One of the key drivers for the growth of the somatropin market is the rising prevalence of growth hormone deficiency. Growth hormone deficiency is a relatively common condition affecting around 1 in 3,800 to 4,000 children worldwide. Some of the key factors contributing to the increasing cases of growth hormone deficiency include genetic disorders, brain tumors, injuries or infections of the brain, and malnutrition during early childhood. The increased adoption of recombinant human growth hormone as a therapeutic option for growth hormone deficiency and other clinical conditions is also fueling the somatropin market growth. Somatropin offers several advantages over the previous bovine-derived somatotropin products in terms of safety, specificity, and effectiveness. This rising preference for recombinant human growth hormone over its bovine-derived predecessors is supporting the market expansion.

SWOT Analysis

Strength: Somatropin has a wide range of clinical applications in the treatment of growth hormone deficiency caused by genetic mutations or acquired conditions. These include Turner syndrome, chronic renal insufficiency, and Prader-Willi syndrome. The medication is administered through subcutaneous injections and can effectively stimulate the body's natural production of somatropin, promoting linear growth in children and boosting muscle mass and bone density in adults.

Weakness: Somatropin treatment requires daily subcutaneous injections over many years, which can be an inconvenience for patients and reduce compliance. The high costs associated with lifelong somatropin therapy also present an economic hurdle for broader access and adoption.

Opportunity: With the patent expiry of branded somatropin formulations, market entry of affordable biosimilar options provide an opportunity to address the current unmet needs of somatropin-deficient patients in lower-income nations. Emerging economies with large patient populations stand to benefit significantly from cheaper biosimilar availability.

Threats: Stringent regulatory standards for biosimilarity and concerns around interchangeability may delay biosimilar uptake in major pharmaceutical markets. Additionally, the development of long-acting somatropin formulations administered through less frequent routes could threaten the market dominance of daily subcutaneous injections.

Key Takeaways

The global Somatropin Market Growth is expected to witness high growth over the forecast period of 2023 to 2030 supported by an increasing patient population and rising healthcare expenditure in developing countries. The market size is estimated to reach US$ 3.85 billion by 2023 and expand at a CAGR of 7.3% through 2030.

Regional analysis

North America currently dominates the somatropin market owing to robust reimbursement structures and widespread clinical adoption in the treatment of growth hormone deficiency and related conditions in the region. However, the Asia Pacific market is poised to emerge as the fastest growing regional market during the forecast period backed by rising incidence of genetic disorders, expanding healthcare infrastructure and growing disposable incomes in countries such as China and India. Continuous technology advancement and increasing collaborations between international drug manufacturers and domestic generic players will further support high market penetration in Asia Pacific over the coming years.

Key players

Key players operating in the somatropin market are Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, Changchun GeneScience Pharmaceutical Co., Ltd., Sandoz International GmbH, Ipsen Pharma, LG Chem, Merck KGaA, Genentech, Inc., Ferring B.V., AnkeBio Co., Ltd, Reliance Life Sciences, JCR Pharmaceuticals Co., Ltd, Zhongshan Sinobioway Hygene Biomedicine Co., Ltd and USV Private Limited.